-
公开(公告)号：EP2059248A1
公开(公告)日：2009-05-20
申请号：EP08707797.0
申请日：2008-02-23
IPC分类号： A61K31/57 , A61K31/573 , A61P15/00
CPC分类号： A61K31/57 , A61K31/573
摘要： A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17α-cyanomethyl-17ß-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetate or chlormadinonacetate at a daily dosage which is no more than two times the dosage required to suppress ovulation, together with one or a plurality of pharmaceutically acceptable adjuvants/carriers. The pharmaceutical composition according to the invention provides both the alleviation of endometriosis and the lack of a negative affect on bone metabolism and bone density, and is simultaneously able to keep the side effects known from conventional pharmaceuticals (such as hot flashes, acne, negative affects on the lipid profile) within tolerable limits. The pharmaceutical composition is thus suitable for long-term application.
-
2.发明公开VERWENDUNG VON GESTAGENEN IN KOMBINATION MIT (6S)5-METHYLTETRAHYDROFOLAT ZUR THERAPIE DER ENDOMETRIOSE MIT GLEICHZEITIGER VERMINDERUNG VON THERAPIE-NEBENWIRKUNGEN SOWIE DER VERMINDERUNG DES RISIKOS ANGEBORENER FEHLBILDUNGEN BEI EINTRITT EINER GRAVIDITÄT 审中-公开孕激素的IN与还原剂先天性畸形的危险妊娠入院治疗和副作用同时减少子宫内膜异位症（6S）-5-甲基四氢叶酸联合治疗中使用
公开(公告)号：EP2194978A1
公开(公告)日：2010-06-16
申请号：EP08785200.0
申请日：2008-07-30
发明人： SEITZ, Christian , WASSERFALL, Annemarie , DIEFENBACH, Konstanze , KING, Kristina , ZIMMERMANN, Holger
IPC分类号： A61K31/195 , A61K31/495 , A61K31/505 , A61K31/519 , A61K31/565 , A61K31/57 , A61P15/02 , A61P15/12 , A61P15/18 , A61P19/10 , A61P43/00
CPC分类号： A61K45/06 , A61K31/195 , A61K31/495 , A61K31/505 , A61K31/519 , A61K31/565 , A61K31/57 , A61K2300/00
摘要： Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations for the therapy of endometrioses with simultaneous reduction of therapy side effects, such as the negative impact on bone density/bone metabolism and the risk for osteoporosis, and in the event of pregnancy, the reduction of the risk on congenital malformations, such as neural tube defects, cheilognathopalatoschisis and complications during pregnancy, such as the detachment of the placenta and premature birth. The invention is suitable for long-term use.
-
搜索结果
2 条记录 (耗时 0.009 秒)
